Not sure we need to speculate on midpoint dosage not working as a likely scenario.
Twice-weekly iPPS group, still showed stabilisation of cartilage preservation and improvements in BML compared to the placebo group.
It's currently being widely administered at various dosage levels to protect joints of various animals
Irrespective FDA will provide guidance on dosage they want to see us use soon enough.
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-245
-
- There are more pages in this discussion • 142 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10756 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 62010 | 3 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |